Source - RNS
RNS Number : 4693O
Genedrive PLC
17 May 2018
 

For release: 17 May 2018

 

 

Circular re Proposed Disposal

Genedrive plc ("the Company")

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, confirms that the circular to shareholders convening a General Meeting for 4 June 2018 in connection with the proposed disposal of the Company's contract research and pharmacogenomics divisions has been posted to shareholders.

Copies of the circular may also be found on the Company's website (www.genedriveplc.com

- Ends -

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO


Matthew Fowler: CFO




Peel Hunt LLP


James Steel

+44 (0)207 418 8900

Oliver Jackson




Consilium Strategic Communications

+44 (0)203 709 5700

Chris Gardner


Matthew Neal


Laura Thornton


[email protected]


 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF assay has been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CIRFKODNNBKDKPD